Accretive named Mike Leavitt, former HHS founder and secretary of a healthcare consulting company, to seat the panel, according to a news release . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an editorially independent news service, is an application of the Kaiser Family Foundation, a nonpartisan health care policy research firm unaffiliated with Kaiser Permanente..It’s the initial long-acting ARV-based item to enter efficacy screening and the first involving an ARV apart from tenofovir or a tenofovir combination. Furthermore, unlike tenofovir, dapivirine is not a drug found in the treatment of HIV. ‘Perhaps the most attractive aspect about a vaginal band as an HIV prevention method is that women may use it discreetly and use it up to a month at a time because of the slow release of the medication it contains. If the women in our trial find it easy and practical to use consistently, this will be extremely important, because just if it is used as directed are we able to assess its true effectiveness,’ said Thesla Palanee, Ph.D., ASPIRE process co-chair who also directs the study at her own organization, the Wits Reproductive Health insurance and HIV Institute in Johannesburg, South Africa.